


Congrès  **CANCER**  
**IMMUNE**

---

# CANCER DE L'IMMUNODÉPRIMÉ

jeudi 19 février 2026 - Paris






Congrès  **CANCER  
IMMUNE**

**CANCER  
DE L'IMMUNODÉPRIMÉ**

jeudi 19 février 2026 - Paris



**Bilan d'activité 2013-2025 de CANCERVIH et  
CANCEROGREF (ex K-VIROGREF)**

Marianne VEYRI, PhD






# Les RCP « cancers rares »





**La RCP « cancers rares » ONCOVIH de 2013 à 2025**





**1717 patients présentés  
2173 dossiers discutés**



### 30 premiers centres 2025 en termes de nombre de dossiers présentés




[omnidoc.fr/cancervih](https://omnidoc.fr/cancervih)





## Type de cancers discutés en RCP





# La RCP « cancers rares » CANCEROGREF 2025




[omnidoc.fr/cancerogref](https://omnidoc.fr/cancerogref)

**12** RCP organisées

**1** via  
omnidoc

Nombre de dossiers  
soumis à la RCP en 2025

**126** demandes d'avis en RCP  
par **28** centres



Nombre total de patients  
présentés en RCP


**103**



72%



28%





## Type de cancers discutés en RCP





# Les DU/DIU



## Le DU Cancer de l'immunodéprimé

2018-2019	2019-2020	2020-2021	2022-2023	2023-2024
6 étudiants	4 étudiants	6 étudiants	16 étudiants	6 étudiants (dont 1 bourse)

**38 étudiants formés**



**D.U.  
Cancer de  
l'immunodéprimé**

Optimiser la prise en charge des patients immunodéprimés atteints de cancers (personnes vivant avec le VIH ou transplantées)

**2023 - 2024**

**Responsables**  
Pr Jean-Philippe Spano  
Dr Sylvain Choquet

**Directrice pédagogique**  
Marianne Veyri

**format à distance**  
Cours en visio-conférence  
en français  
Novembre 2023 à mai 2024

**Plaquette  
pédagogique**

Renseignements : Marianne Veyri  
marianne.veyri@aphp.fr





[www.cancervih.org](http://www.cancervih.org)





## Le DIU « Cancer et virus »

2023-2024	2024-2025	2025-2026
5 étudiants	annulé	6 étudiants

**11 étudiants formés (ou en cours)**




2023  
2024

**NOUVEAU**

### DIU VIRUS ET CANCER


Optimiser la prévention, le diagnostic et la prise en charge des cancers viro-induits. Approfondir les possibilités des virus en tant que thérapeutique anti-tumorale.

 **Cours en présentiel**

12 jours de cours 6 modules  
entre novembre et mai

**Public concerné :**

Docteurs en médecine  
Chefs de clinique Assistants, Internes  
Formation continue post-doctorale  
Docteurs en science

 **Responsables :**


- Pr Arélien MARABELLE
- Pr Jean-Philippe STRAND
- Pr Christine KATLAMA


- Dr Judith MICHELS
- Dr Lucie VERON
- Dr Philippe GORPHE
- Dr Jérôme DURAND LABRUNIE
- Dr Stéphane CHAMPIAT
- Dr Claire DEBACK
- Dr Hélène PERE

**RENSEIGNEMENTS**

Stéphanie Doucet  
Assistante d'enseignement  
Tél. 01 42 11 52 58  
Mail : stephanie.doucet@gustaveroussy.fr

Date limite de candidature :  
avant le 7 octobre 2023

 **Plus d'infos & contact :**  
[enseignement.gustaveroussy.fr](mailto:enseignement.gustaveroussy.fr)





# Les publications

# Les publications 2013-2024 : plus de 100 référencées PubMed

Abbar B. et al. HIV and cancer: Update 2020. Bull Cancer. 2020.

Abbar B. et al. Immune checkpoint inhibitors in people living with HIV: what about anti-HIV effects? AIDS. 2020.

Spano JP. et al. Cancer and HIV. Bull Cancer 2014.

Veyri M et al. Do people living with HIV face more secondary cancers than general population: From the French CANCERVIH network. Bull Cancer. 2021.

Taouqi M et al. Survey on HIV, HBV and HCV screening practices in cancerology, France. Bull Cancer. 2021.

Guihot A et al. Drastic decrease of the HIV reservoir in a patient treated with nivolumab for lung cancer. Ann Oncol. 2018.

Makinson A et al. Lung Cancer Screening with Chest Computed Tomography in People Living with HIV: A Review by the Multidisciplinary CANCERVIH Working Group. J Thorac Oncol. 2016.

Gobert A. et al. HIV-related malignancies: state of art. Bull Cancer 2014.

Lavolé A et al. French Cooperative Thoracic Intergroup (IFCT). First-line carboplatin plus pemetrexed with pemetrexed maintenance in HIV-positive patients with advanced non-squamous non-small cell lung cancer: the phase II IFCT-1001 CHIVA trial. Eur Respir J. 2020.

Abbar B et al. Non-AIDS-defining cancers in people living with HIV. Lancet Oncol. 2021.

Spano JP et al. Immunotherapy for cancer in people living with HIV: safety with an efficacy signal from the series in real life experience. AIDS. 2019.

Gobert A et al. HIV and cancer : What's new in 2017? Bull Cancer. 2018.

Assoumou L et al. Safety and tolerability of immune checkpoint inhibitors in people with HIV infection and cancer: insights from the national prospective real-world OncoVIHAC ANRS CO24 cohort study. J Immunother Cancer. 2024.

Quéro L et al. Radiotherapy for HIV-infected patients. Cancer Radiother. 2018.

Gobert A, Spano JP, Cadranel J. HIV-associated cancers: the role of a unique multidisciplinary board to optimize patient's care behalf the CANCERVIH Group. Med Oncol. 2018.

Lavolé A et al. On behalf the French Cooperative Thoracic Intergroup (IFCT). Assessment of nivolumab in HIV-Infected patients with advanced non-small cell lung cancer after prior chemotherapy. The IFCT-1602 CHIVA2 phase 2 clinical trial. Lung Cancer. 2021.

Baron M et al. , The French Cooperative Thoracic Intergroup Ifct Chiva-Investigators, The Anrs Co OncoVIHAC Study Group. Impact of Anti PD-1 Immunotherapy on HIV Reservoir and Anti-Viral Immune Responses in People Living with HIV and Cancer. Cells. 2022.

Le Garff G et al. Transient HIV-specific T cells increase and inflammation in an HIV-infected patient treated with nivolumab. AIDS. 2017.

Palich R et al. CancerVIH Study Group. Recurrence and Occurrence of Kaposi's Sarcoma in Patients Living With Human Immunodeficiency Virus (HIV) and on Antiretroviral Therapy, Despite Suppressed HIV Viremia. Clin Infect Dis. 2020.

Spano JP et al. Non-AIDS-related malignancies: expert consensus review and practical applications from the multidisciplinary CANCERVIH Working Group. Ann Oncol. 2016.

Bruyand M et al. Protease inhibitors exposure is not related to lung cancer risk in HIV smoker patients: a nested case-control study. AIDS. 2015.

Guihot A et al. Biological follow-up of patients with HIV treated with anti-PD-1 or anti-PD-L1 for non-small cell bronchial carcinoma: A task group proposal. Rev Mal Respir. 2016.

Lavolé A et al. PD-1 blockade in HIV-infected patients with lung cancer: a new challenge or already a strategy? Ann Oncol. 2018.

# Les publications 2013-2024 : plus de 100 référencées PubMed

Trappe RU et al. Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial. *J Clin Oncol.* 2017.

Gauci ML et al., European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization for Research and Treatment of Cancer (EORTC). Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline - Update 2022. *Eur J Cancer.* 2022.

Delyon J et al. Skin Care in Organ Transplant Patients Europe (SCOPE) group. Management of Kaposi sarcoma after solid organ transplantation: A European retrospective study. *J Am Acad Dermatol.* 2019.

Caillard S et al. Post-transplantation lymphoproliferative disorder after kidney transplantation: report of a nationwide French registry and the development of a new prognostic score. *J Clin Oncol.* 2013.

Dharnidharka VR, Webster AC, Martinez OM, Preiksaitis JK, Leblond V, Choquet S. Post-transplant lymphoproliferative disorders. *Nat Rev Dis Primers.* 2016.

Trappe RU et al. German PTLD Study Group and the European PTLD Network. International prognostic index, type of transplant and response to rituximab are key parameters to tailor treatment in adults with CD20-positive B cell PTLD: clues from the PTLD-1 trial. *Am J Transplant.* 2015.

Chaganti S et al. Expert Consensus on the Characteristics of Patients with Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) for Whom Standard-Dose Chemotherapy May be Inappropriate: A Modified Delphi Study. *Adv Ther.* 2023.

Zimmermann H et al. Immunosuppression Is Associated With Clinical Features and Relapse Risk of B Cell Posttransplant Lymphoproliferative Disorder: A Retrospective Analysis Based on the Prospective, International, Multicenter PTLD-1 Trials. *Transplantation.* 2018.

Morland D et al. K-VIROGREF Study Group; Durot E. Cerebellum/liver index on baseline 18F-FDG PET/CT to improve prognostication in post-transplant lymphoproliferative disorders: a multicenter retrospective study. *EJNMMI Res.* 2024.

Zimmermann H, et al. Baseline differential blood count and prognosis in CD20-positive post-transplant lymphoproliferative disorder in the prospective PTLD-1 trial. *Leukemia.* 2013.

Evens AM et al. Primary CNS posttransplant lymphoproliferative disease (PTLD): an international report of 84 cases in the modern era. *Am J Transplant.* 2013.

Choquet S et al. Adapted treatment of Epstein-Barr virus infection to prevent posttransplant lymphoproliferative disorder after heart transplantation. *Am J Transplant.* 2014.

Nakid-Cordero C et al. K-VIROGREF Study Group. Distinct immunopathological mechanisms of EBV-positive and EBV-negative posttransplant lymphoproliferative disorders. *Am J Transplant.* 2021.

Morland D et al. Baseline 18F-FDG Metabolic Tumor Volume Predicts Response to Rituximab Induction in Post-transplant Lymphoproliferative Disorders: A Multi-institutional Retrospective Study. *Hemasphere.* 2023.



**Retifanlimab with carboplatin and paclitaxel for locally recurrent or metastatic squamous cell carcinoma of the anal canal (PODIUM-303/InterAACT-2): a global, phase 3 randomised controlled trial.**

Sheela Rao, Emmanuelle Samalin-Scalzi, Ludovic Evesque, Meher Ben Abdelghani, Federica Morano, Amitesh Roy, Laetitia Dahan, Stefano Tamperi, Amandeep Singh Dhadda, Mark P Saunders, Nathalie Casanova, Rosine Guimbaud, Astrid Lievre, Joan Maurel, Marwan Fakih, Chuan Tian, Jill Harrison, Mark M Jones, Mark Cornfeld, Jean-Philippe Spano, Pauline Rochefort, for the PODIUM-303/InterAACT-2 study investigators.

**The Lancet. Volume 405, Issue 10495. p2144-2152. June 14, 2025.**

THE LANCET



**Human Immunodeficiency Virus Impairs Immune Responses to Tumor Neoepitopes Without Altering Mutational Profiles in NSCLC.**

Abbar B, Labreche K, Cadranet J, Veyri M, Morin V, Thiam FS, Desire N, Baron M, Guillem E, Perrier A, Fallet V, Maitre T, Canellas A, Tarantino N, Mze O, Samri A, Dejancourt L, Nakid-Cordero C, Vozy A, Picca A, Touat M, Guihot A, Chouaid C, Mokhtari K, Bielle F, Brocheriou I, Rouvier P, Osorio AR, Buob D, Bouzidi A, Marie Y, Assouad J, Boelle PY, Coulet F, Vieillard V, Spano JP, Autran B.

**J Thorac Oncol. 2025 Jul;20(7):897-911.**





**Impacts of immune checkpoint inhibitors use on the HIV reservoir are linked to provirus sequences but not integration sites.**

Guiraud V, Fauchois A, Soulie C, Leducq V, Veyri M, Assoumou L, Boutolleau D, Costagliola D, Lambotte O, Spano JP, Pourcher V, Marcelin AG, Calvez V.

**Sci Rep. 2025 Aug 28;15(1):31726.**

SCIENTIFIC REPORTS



**Soluble CD95L is a prognostic marker in central nervous system posttransplant lymphoproliferative disorders.**

Tichadou A, Lebrault E, Samri A, Baron M, Nakid-Cordero C, Lavergne D, Morin V, Mze O, Balegrone N, Liang X, Choquet S, Guihot A, Legembre P, Roussel M. K-VIROGREF Study Group.

**Am J Transplant. 2025 Oct;25(10):2127-2141.**

American Journal of  
TRANSPLANTATION



**Projecting changes in demographics and causes of death in people with HIV in western Europe from 2025 to 2050: a mathematical modelling study.**

Ambia J, van Sighem A, Pantazis N, Gill MJ, Grabar S, Monforte AD, Zangerle R, Bruguera A, Teira R, Jarrin I, Vehreschild J, Cavassini M, van der Valk M, Bonnet F, Sterne JAC, Ingle SM, Trickey A.

**Lancet HIV. 2025 Nov 7:S2352-3018(25)00197-3.**

THE LANCET  
HIV







Déjà des publications communes...

Gobert A, Veyri M, Balegroune N, Leblond V, Spano JP, Choquet S. Spécificités des cancers chez les patients immunodéprimés. Correspondances en Onco-Hématologie. 2018.

Baron M, Labreche K, Veyri M, Désiré N, Bouzidi A, Seck-Thiam F, Charlotte F, Rousseau A, Morin V, Nakid-Cordero C, Abbar B, Picca A, Le Cann M, Balegroune N, Gauthier N, Theodorou I, Touat M, Morel V, Bielle F, Samri A, Alentorn A, Sanson M, Roos-Weil D, Haioun C, Poullot E, De Septenville AL, Davi F, Guihot A, Boelle PY, Leblond V, Coulet F, Spano JP, Choquet S, Autran B. Epstein-Barr virus and immune status imprint the immunogenomics of non-Hodgkin lymphomas occurring in immune-suppressed environments. Haematologica. 2024.

Zafilaza K, Fauchois A, Leducq V, Coppée R, Guilbaud R, Yusti AF, Todesco E, Bridier-Nahmias A, Hingrat QL, Choquet S, Cacoub P, Amoura Z, Barrou B, Pourcher V, Spano JP, Louet M, Kramer L, Goulenok T, Salpin M, Daugas E, Dorent R, Ottaviani S, Zalcman G, Ghosn J, Charpentier C, Descamps D, Marcelin AG, Calvez V, Ferre VM, Marot S, Soulie C. SARS-CoV-2 lineage-dependent temporal phylogenetic distribution and viral load in immunocompromised and immunocompetent individuals. Virol J. 2025.



# Les présentations en congrès



Congrès  **CANCER IMMUNE**

**CANCER DE L'IMMUNODÉPRIMÉ**

 **9<sup>ÈMES</sup> JSIC** | Journées Scientifiques Immunité et Cancer  
*Mieux comprendre pour mieux traiter*

**ASCO**<sup>®</sup>  
ANNUAL MEETING

 **ICML** | International Conference on Malignant Lymphoma  
**Lugano** Advancing lymphoma science since 1981



 **ESOT Congress**  
THE INTERNATIONAL TRANSPLANT CONGRESS<sup>®</sup>

 **IAS 2025**

 **soho**  
society of hematologic oncology

Complications & Comorbidités

 **EBMT**



22<sup>e</sup> Edition  
**Synergie Résistances**  
& Immunosuppression

**ESMO**

 **IFODS**  
Le Congrès National d'Oncologie

 **AFRAVIH**  
FRANCOPHONE DES ACTEURS DE SANTÉ COI  
INFECTIONS VIRALES CHRONIQUES OU EMEI

 **AFSOS**  
Association Francophone des Soins Oncologiques de Support

 **sfh**  
Société Française d'Hématologie

 **isheid**  
16-18 MAY 2018

Suivez notre actualité sur nos pages



k-virogref.org



cancervih.org



# Les actions communes avec les associations / collectifs de patients

## 3 représentants d'associations ou collectifs de patients au Conseil Scientifique CANCERIMMUNE



## Participation de CANCERVIH à la rédaction de brochures d'associations de patients



## Vidéos explicatives pour les patients

- ACTIONS TRAITEMENTS, Pr. Jean-Philippe Spano, Marianne Veyri



## Représentation dans des comités scientifiques d'associations de patients

- Dr Sylvain Choquet  ensemble leucémie lymphomes espoir

## Participation des associations de patients à des tables rondes dans les événements CANCERIMMUNE



## Participation à des webinaires pour les patients

- ACTIONS TRAITEMENTS, 26/11/2024, Dr Alain Makinson, Dr Sophie Grabar, Marianne Veyri
- ELLYE, 2024, Dr Sylvain Choquet



## Participation d'associations et collectifs de patients à la rédaction du livret d'information patients



## Participation d'associations et collectifs de patients au DU Cancer de l'immunodéprimé




## Participation à des ateliers pour les patients

- ARTEMIS MEDICA, 03/05/2023, Dr Baptiste Abbar
- AIDES, 10/04/2024, Marianne Veyri
- Actions traitements, 21/09/2024, Pr. Jean-Philippe Spano
- Comité des familles, 14/11/2024, Marianne Veyri

## ATELIERS PATIENTS

### RÉDUIRE LES RISQUES DE CANCER

LE 23 SEPTEMBRE 2025

 Actions traitements - 23 rue Duris - 75020 Paris

dispensé par Marianne Veyri pour 

### VIH ET CANCERS

LE 25 SEPTEMBRE 2025

 Comité des familles - 18 rue de la Mare - 75020 Paris

dispensé par Marianne Veyri pour 

# Congrès **CANCER** **IMMUNE**

## CANCER DE L'IMMUNODÉPRIMÉ

avec le soutien et le parrainage de

